JP2020535162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535162A5 JP2020535162A5 JP2020517419A JP2020517419A JP2020535162A5 JP 2020535162 A5 JP2020535162 A5 JP 2020535162A5 JP 2020517419 A JP2020517419 A JP 2020517419A JP 2020517419 A JP2020517419 A JP 2020517419A JP 2020535162 A5 JP2020535162 A5 JP 2020535162A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- pharmaceutical composition
- polymer matrix
- film according
- pharmaceutical film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims description 38
- 239000011159 matrix material Substances 0.000 claims description 30
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 13
- 239000000419 plant extract Substances 0.000 claims description 12
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 11
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 11
- 229960005139 epinephrine Drugs 0.000 claims description 11
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 9
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 9
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 229930015704 phenylpropanoid Natural products 0.000 claims description 8
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 239000003961 penetration enhancing agent Substances 0.000 claims description 5
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 4
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 claims description 4
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 4
- 239000005770 Eugenol Substances 0.000 claims description 4
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 4
- RGIBXDHONMXTLI-UHFFFAOYSA-N chavicol Chemical compound OC1=CC=C(CC=C)C=C1 RGIBXDHONMXTLI-UHFFFAOYSA-N 0.000 claims description 4
- 229930016911 cinnamic acid Natural products 0.000 claims description 4
- 235000013985 cinnamic acid Nutrition 0.000 claims description 4
- 229960002217 eugenol Drugs 0.000 claims description 4
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 4
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 claims description 4
- -1 labrazole Natural products 0.000 claims description 3
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 2
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 2
- IAZKGRRJAULWNS-UHFFFAOYSA-N Chavicol Natural products OC1=CC=C(CCC=C)C=C1 IAZKGRRJAULWNS-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 230000001851 biosynthetic effect Effects 0.000 claims description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 2
- 229930002886 farnesol Natural products 0.000 claims description 2
- 229940043259 farnesol Drugs 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 2
- 244000223014 Syzygium aromaticum Species 0.000 claims 4
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 45
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 244000061408 Eugenia caryophyllata Species 0.000 description 4
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010058151 Pulseless electrical activity Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229930014594 aporphine alkaloid Natural products 0.000 description 1
- 150000008441 aporphines Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 208000021816 ventricular bradycardia Diseases 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023126682A JP2023159150A (ja) | 2017-09-27 | 2023-08-03 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2025173124A JP2026027254A (ja) | 2017-09-27 | 2025-10-14 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/717,859 | 2017-09-27 | ||
| US15/717,859 US20180125977A1 (en) | 2016-05-05 | 2017-09-27 | Enhanced delivery epinephrine compositions |
| US15/791,249 | 2017-10-23 | ||
| US15/791,249 US12427121B2 (en) | 2016-05-05 | 2017-10-23 | Enhanced delivery epinephrine compositions |
| PCT/US2018/053042 WO2019067670A1 (en) | 2017-09-27 | 2018-09-27 | EPINEPHRINE AND ENHANCED DELIVERY COMPOSITIONS |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126682A Division JP2023159150A (ja) | 2017-09-27 | 2023-08-03 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2025173124A Division JP2026027254A (ja) | 2017-09-27 | 2025-10-14 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535162A JP2020535162A (ja) | 2020-12-03 |
| JP2020535162A5 true JP2020535162A5 (https=) | 2021-12-16 |
Family
ID=63858169
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517419A Pending JP2020535162A (ja) | 2017-09-27 | 2018-09-27 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2023126682A Pending JP2023159150A (ja) | 2017-09-27 | 2023-08-03 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2025173124A Pending JP2026027254A (ja) | 2017-09-27 | 2025-10-14 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126682A Pending JP2023159150A (ja) | 2017-09-27 | 2023-08-03 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
| JP2025173124A Pending JP2026027254A (ja) | 2017-09-27 | 2025-10-14 | 増強された送達のエピネフリン及びプロドラッグ組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3687510A1 (https=) |
| JP (3) | JP2020535162A (https=) |
| KR (1) | KR20200060748A (https=) |
| CN (1) | CN111465391A (https=) |
| BR (1) | BR112020005948A2 (https=) |
| CA (1) | CA3076816A1 (https=) |
| IL (2) | IL313551A (https=) |
| WO (1) | WO2019067670A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| KR20230137362A (ko) | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| BR112022008294A2 (pt) * | 2019-11-01 | 2022-07-26 | Aquestive Therapeutics Inc | Composições de profármaco e métodos de tratamento |
| US11571468B2 (en) * | 2021-02-01 | 2023-02-07 | Matthias W. Rath | Micronutrient combination to reduce blood pressure |
| EP4422607A4 (en) | 2021-10-25 | 2025-09-03 | Aquestive Therapeutics Inc | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT |
| US20240016734A1 (en) * | 2022-06-14 | 2024-01-18 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| EP4302751A1 (en) * | 2022-07-07 | 2024-01-10 | LTS Lohmann Therapie-Systeme AG | Oral thin films with low water activity |
| CN118121542A (zh) * | 2023-03-31 | 2024-06-04 | 中国药科大学 | 鼻用药物组合物、其制备方法及应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US20030143195A1 (en) * | 2002-01-30 | 2003-07-31 | Pinsker Judy Senior | Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| US20040096569A1 (en) * | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| US20050266085A1 (en) * | 2004-05-28 | 2005-12-01 | Warner Kevin S | Gelled emulsion and microemulsion formulations for dermal drug delivery |
| US20070202163A1 (en) * | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| US20070293581A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies |
| US20070293582A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| PE20091084A1 (es) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal |
| JP2012524771A (ja) * | 2009-04-23 | 2012-10-18 | ロンドンファーマ リミテッド | 中性油を含む舌下用の医薬組成物 |
| EP2552486B1 (en) * | 2010-03-30 | 2020-08-12 | Phosphagenics Limited | Transdermal delivery patch |
| KR20140084176A (ko) * | 2011-10-28 | 2014-07-04 | 권성윤 | 편두통을 치료하기 위한 용해성 고용체 퍼포레이터 패치 |
| SG11201502425WA (en) * | 2012-10-11 | 2015-05-28 | Ix Biopharma Ltd | Solid dosage form |
| US20160051494A1 (en) * | 2014-08-21 | 2016-02-25 | Mylan, Inc. | Multi-dose medication kit for treating anaphylaxis |
| KR20230137362A (ko) * | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| WO2017192923A1 (en) * | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Pharmaceutical compositions with enhanced permeation |
| EP3687508A1 (en) * | 2017-09-26 | 2020-08-05 | Aquestive Therapeutics, Inc. | Delivery pharmaceutical compositions including permeation enhancers |
-
2018
- 2018-09-27 IL IL313551A patent/IL313551A/en unknown
- 2018-09-27 CN CN201880063175.3A patent/CN111465391A/zh active Pending
- 2018-09-27 CA CA3076816A patent/CA3076816A1/en active Pending
- 2018-09-27 WO PCT/US2018/053042 patent/WO2019067670A1/en not_active Ceased
- 2018-09-27 EP EP18786593.6A patent/EP3687510A1/en active Pending
- 2018-09-27 KR KR1020207012106A patent/KR20200060748A/ko not_active Ceased
- 2018-09-27 IL IL273485A patent/IL273485B2/en unknown
- 2018-09-27 BR BR112020005948-0A patent/BR112020005948A2/pt unknown
- 2018-09-27 JP JP2020517419A patent/JP2020535162A/ja active Pending
-
2023
- 2023-08-03 JP JP2023126682A patent/JP2023159150A/ja active Pending
-
2025
- 2025-10-14 JP JP2025173124A patent/JP2026027254A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535162A5 (https=) | ||
| JP2020535176A5 (https=) | ||
| IL273485B2 (en) | Enhanced delivery epinephrine and prodrug compositions | |
| JP6770157B2 (ja) | 特定の投薬量の活性物質を皮膚又は粘膜に投与するための電気流体力学的に得られた繊維を含む組成物 | |
| Arafa et al. | Propolis-based niosomes as oromuco-adhesive films: A randomized clinical trial of a therapeutic drug delivery platform for the treatment of oral recurrent aphthous ulcers | |
| RU2245715C2 (ru) | Композиция лака для ногтей | |
| JP5841151B2 (ja) | 鼻腔噴霧剤 | |
| RU2701513C2 (ru) | Фармацевтическая композиция, содержащая электрогидродинамически полученные волокна, композиция, имеющая улучшенное время удержания в месте применения | |
| EP3381448B1 (en) | Oral hemostatic and wound-protective film | |
| JP2019519488A5 (https=) | ||
| JP6491647B2 (ja) | キトサンペースト創傷手当て材 | |
| IL273479B1 (en) | Pharmaceutical compositions with enhanced permeation | |
| JP2019519487A5 (https=) | ||
| Hamman et al. | Use of natural gums and mucilages as pharmaceutical excipients | |
| ME00828B (me) | Upotreba hitozana za lečenje inflamatornih oboljenja noktiju | |
| CN114845700A (zh) | Otf的可溶性背衬层 | |
| CN102018686A (zh) | 含有丝裂霉素的膜剂及其制备方法 | |
| Kumar et al. | Natural excipients: A review | |
| JP2018177724A (ja) | 外用薬 | |
| CN102178644A (zh) | 马来酸噻吗洛尔眼用凝胶剂及其制备方法 | |
| KR101333892B1 (ko) | 항진균 조성물 | |
| CN114376964B (zh) | 一种葛根素纳米粒成膜水凝胶制剂及其制备方法 | |
| JP2018177725A (ja) | 外用薬 | |
| US20190314325A1 (en) | Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management | |
| EA029402B1 (ru) | Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей, комбинированный трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей и способ его получения |